Search

Your search keyword '"R, Creech"' showing total 7 results
Start Over Author "R, Creech" Topic doxorubicin
7 results on '"R, Creech"'

1. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.

Author

Bruckner HW, Pagano M, Falkson G, Creech R, Arseneau JC, Horton J, Brodovsky H, Davis TE, Slayton RW, and Greenspan E

Subjects
Clinical Trials as Topic, Drug Evaluation, Drug Therapy, Combination, Female, Humans, Melphalan administration & dosage, Methotrexate administration & dosage, Middle Aged, Organothiophosphorus Compounds administration & dosage, Remission, Spontaneous, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Fluorouracil administration & dosage, Ovarian Neoplasms drug therapy
Published
1979

2. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer.

Author

Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, and Hahn RG

Subjects
Bone Marrow drug effects, Cyclophosphamide adverse effects, Doxorubicin adverse effects, Female, Humans, Neoplasm Metastasis drug therapy, Remission, Spontaneous, Adenocarcinoma drug therapy, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Uterine Neoplasms drug therapy
Published
1978

4. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.

Author

DeWys WD, Begg CB, Brodovsky H, Creech R, and Khandekar J

Subjects
Acid Phosphatase blood, Adenocarcinoma blood, Clinical Trials as Topic, Doxorubicin adverse effects, Fluorouracil adverse effects, Humans, Male, Prognosis, Prostatic Neoplasms blood, Adenocarcinoma drug therapy, Doxorubicin therapeutic use, Fluorouracil therapeutic use, Prostatic Neoplasms drug therapy
Abstract

In patients with metastatic hormone-relapsed adenocarcinoma of the prostate, adriamycin was compared to 5-fluorouracil in a randomized trial in 99 patients and adriamycin alone was studied in an open trial in 48 patients. Response to adriamycin was superior as judged by response of measurable disease (25 vs 8%; P less than 0.05) and survival (median 29 vs 24 weeks; Cox analysis, P less than 0.03), but comparable as judged by acid phosphatase response. Ambulatory status and site of metastases influenced rate of response to chemotherapy. Activity level, site of metastases, weight loss, and the symptom of protein aversion were prognostic factors for survival. Hematologic and gastrointestinal toxicity were frequent but were tolerated satisfactorily. Adriamycin therapy may be beneficial in patients with prostatic cancer after hormone therapy.

Published
1983
Full Text
View/download PDF

6. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report

Author

H W, Bruckner, M, Pagano, G, Falkson, R, Creech, J C, Arseneau, J, Horton, H, Brodovsky, T E, Davis, R W, Slayton, and E, Greenspan

Subjects
Ovarian Neoplasms, Clinical Trials as Topic, Remission, Spontaneous, Organothiophosphorus Compounds, Middle Aged, Methotrexate, Doxorubicin, Drug Evaluation, Humans, Drug Therapy, Combination, Female, Fluorouracil, Cyclophosphamide, Melphalan
Published
1979

Catalog

Books, media, physical & digital resources
See catalog results